Immunic Announces Participation in Key Conferences

Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focused on small molecule therapies, will engage in prominent investor and scientific conferences this September. The agenda includes participation at the H.C. Wainwright 27th Annual Global Investment Conference in New York, the Leerink Partners Biopharma Summit in California, and the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona. Notably, data on their lead-asset, vidofludimus calcium (IMU-838), will be presented at ECTRIMS. This includes an oral presentation by Dr. Robert J. Fox and several poster sessions showcasing its efficacy and safety in multiple sclerosis.

Immunic’s executive team, including CEO Daniel Vitt and President Jason Tardio, will actively participate in these events, aiming to highlight ongoing advancements and engage with potential investors and stakeholders. For more information on the events and presentations, interested parties can visit the company's website.